Skip to main content
Navigate Up
Sign In

Welcome to the Department of Neurology

Neurology Banner Image
 

Neuroimmunology/MS

Clinical Trials



If you think you may qualify for one of these studies, please contact Professional Research Assistant (PRA) below for more information.

Search for: (view all)

Title Principal Investigator PRA
A Phase IV Trial of Neuroprotection with ACTH in Acute Optic Neuritis Bennett, Jeffrey L., MD, PhD Ruth Johnson
303-724-7885
Eligibility and Information
Analysis of B-cell Trafficking in Multiple Sclerosis Patients Receiveing Tysabri(R) (natalizumab) and Gilenya (fingolimod) Immunomodulatory Therapy Bennett, Jeffrey L., MD, PhD Ruth Johnson
303-724-7885
Please contact PRA for eligibility and information
The role of TH40 cell in Multiple Sclerosis and Type 1 Diabetes Corboy, John R., MD MS Hotline
303-724-4644
Please contact PRA for eligibility and information
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis Corboy, John R., MD MS Hotline
303-724-4644
Eligibility and Information
A DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF ESTRIOL TREATMENT IN WOMEN WITH MULTIPLE SCLEROSIS: EFFECT ON COGNITION. Corboy, John R., MD MS Hotline
303-724-4644
Eligibility and Information
Rocky Mountain MS Center Tissue Bank Corboy, John R., MD MS Hotline
303-724-4644
Please contact PRA for eligibility and information
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Corboy, John R., MD MS Hotline
303-724-4644
Eligibility and Information
Vestibular rehabilitation for persons with Multiple Sclerosis: what benefits are possible Jeffery Hebert, PT, PhD MS Hotline
303-724-4644
Eligibility and Information
A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND ACTIVITY OF IBUDILAST (MN-166) IN SUBJECTS WITH PROGRESSIVE MULTIPLE SCLEROSIS Miravalle, Augusto A., MD Kathryn Connelly
303-724-3736
Eligibility and Information
Improving bladder care for patients with Multiple Sclerosis. Developing a systematic approach for the assessment and diagnosis of neurogenic bladder in Multiple Sclerosis (MS) patients will result in improved bladder care and health related outcomes Miravalle, Augusto A., MD MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs) Miravalle, Augusto A., MD Brooke Valdez
303-724-4177
Please contact PRA for eligibility and information
Effectiveness Analysis of Natalizumab versus Fingolimod using Patient-Reported Outcomes in Patients with Multiple Sclerosis Nair, Kavita PhD MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Cross-Sectional Study of MSDx Complex-1 Association with Gadolinium Enhancing Lesions in Relapsing-Remitting Multiple Sclerosis Schreiner, Teri L., MD, MPH MS Hotline
303-724-4644
Eligibility and Information
Medication Adherence in Pediatric Multiple Sclerosis Schreiner, Teri L., MD, MPH MS Hotline
303-724-4644
Please contact PRA for eligibility and information
A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patient Schreiner, Teri L., MD, MPH MS Hotline
303-724-4644
Eligibility and Information
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of BG00012 When Used in Routine Medical Practice in the Treatment of Relapsing Multiple Sclerosis Schreiner, Teri L., MD, MPH MS Hotline
303-724-4644
Eligibility and Information
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis Schreiner, Teri L., MD, MPH MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Pediatric Multiple Sclerosis and other Demyelinating Diseases Database (PeMSDD Database) Schreiner, Teri L., MD, MPH MS Hotline
303-724-4644
Please contact PRA for eligibility and information
Two-year, Double-blind, Randomzied, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis Schreiner, Teri L., MD, MPH MS Hotline
303-724-4644
Eligibility and Information
A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS) Vollmer, Timothy L., MD MS Hotline
303-724-4644
Eligibility and Information
Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders Vollmer, Timothy L., MD Brooke Valdez
303-724-4177
Please contact PRA for eligibility and information
Patient Reported Outcomes (PROs) as Part of Routine Clinical Care in the Rocky Mountain Multiple Sclerosis Center (RMMSC) Neuroimmunology Department Vollmer, Timothy L., MD MS Hotline
303-724-4177
Please contact PRA for eligibility and information
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy West, Matthew S., MD MS Hotline
303-724-4644
Eligibility and Information